Prevalence of Helicobacter pylori positivity in patients undergoing percutaneous coronary intervention

Internal Medicine Journal

Volumn 42, Issue 3, 2012, Pages 289-293

  Hiew, C ^a   Duggan, A ^a   de Malmanche, T ^a   Hatton, R ^a   Baker, F ^a   Attia, J ^a   Collins, N ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Antiplatelet drugs; Coronary artery disease; Gastrointestinal haemorrhage; Helicobacter pylori; Percutaneous coronary intervention

Indexed keywords

CREATININE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARE METAL STENT; CREATININE BLOOD LEVEL; DRUG ELUTING STENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GROUPS BY AGE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROLOGY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, BACTERIAL; COHORT STUDIES; COMORBIDITY; CREATININE; DISEASE SUSCEPTIBILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; NEW SOUTH WALES; PEPTIC ULCER; PEPTIC ULCER HEMORRHAGE; PLATELET AGGREGATION INHIBITORS; PREDNISONE; PROTON PUMP INHIBITORS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; STENTS;

EID: 84858714010     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02260.x     Document Type: Article

References (28)

1. Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schomig A etal. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 2008; 51: 690-7.
2. Nikolsky EMR, Lansky A, Caixeta A, Dangas GB, Weisz G, Giuran IB etal. Impact of gastrointestinal bleeding on outcomes of patients treated with contemporary antithrombotic strategies: pooled analysis from 3 randomized trials. J Am Coll Cardiol 2009; 53(10 Suppl A): A28.
3. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D etal. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-30.
4. Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI etal. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) pilot trial. Circulation 2005; 111: 1390-7.
5. Mehta SR, Granger CB, Eikelboom JW, Bassand JP, Wallentin L, Faxon DP etal. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50: 1742-51.
6. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007; 115: 1440-55; discussion 1455.
7. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C etal. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-91.
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
9. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO etal. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
10. Garg R, Uretsky BF, Lev EI. Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2007; 70: 388-406.
11. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S etal. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.
12. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
13. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M etal. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362-8.
14. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ etal. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28: 1936-45.
15. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007; 23: 163-73.
16. Kaffes A, Cullen J, Mitchell H etal. Effect of Helicobacter pylori infection and low-dose aspirin use on iron stores in the elderly. J Gastroenterol Hepatol 2003; 18: 1024-8.
17. Scheiman JM. Strategies to reduce the GI risks of antiplatelet therapy. Rev Cardiovasc Med 2005; 6(Suppl 4): S23-31.
18. Zullo A, Hassan C, Campo SM, Morini S. Bleeding peptic ulcer in the elderly: risk factors and prevention strategies. Drugs Aging 2007; 24: 815-28.
19. Banks LWJ, Marks IN. Peptic ulcer: a follow-up study. J Clin Gastroenterol 1986; 8: 381-4.
20. Younger J, Duggan A. Helicobacter pylori infection in elderly patients. Lancet 2002; 360: 947; author reply 948.
21. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung VK etal. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73.
22. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
23. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol 2009; 44(Suppl 19): 44-52.
24. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-60.
25. Lin SK, Lambert JR, Nicholson L, Lukito W, Wahlqvist M. Prevalence of Helicobacter pylori in a representative Anglo-Celtic population of urban Melbourne. J Gastroenterol Hepatol 1998; 13: 505-10.
26. Moujaber T, MacIntyre CR, Backhouse J, Gidding H, Quinn H, Gilbert GL. The seroepidemiology of Helicobacter pylori infection in Australia. Int J Infect Dis 2008; 12: 500-4.
27. Windsor HM, Abioye-Kuteyi EA, Leber JM, Morrow SD, Bulsara MK, Marshall BJ. Prevalence of Helicobacter pylori in Indigenous Western Australians: comparison between urban and remote rural populations. Med J Aust 2005; 182: 210-13.
28. Bruce MG, Maaroos HI. Epidemiology of Helicobacter pylori infection. Helicobacter 2008; 13(Suppl 1): 1-6.